Company Overview and News
Johnson & Johnson (JNJ - Free Report) set the 2018 pharma earnings in motion by beating the Zacks Consensus Estimate on both counts in the second quarter of 2018. The drug and consumer products giant however narrowed its full year sales forecast, due to lower-than-previously expected currency tailwinds. The guidance cut pulled down shares initially in pre-market trading. However, the stock picked up thereafter and rose 1.
ALXN JNJ ABBV ABBV
(Reuters) - AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie’s blockbuster drug Humira, in a move that will give it more near-term control over the competition.
AMGN BIIB ABBV ABBV
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ CNXR VRX ABBV 500680 PFE PFIZER ABBV
Discussion: Zogenix (ZGNX) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe form of epilepsy in children and young adults. Patients in the group under trial experienced a significant betterment, of 54.7% (compared to placebo) decrease in mean monthly convulsive seizures. Both the key secondary endpoints were also met by the trial results.
SGEN AST.WS XLRN AST XNCR CELG GSK ABBV ZYNE ZGNX GSK ABBV
The first half of 2018 is already over, so it is time to look back at how our portfolio performed, the purchases we made and to check our income growth.
SOJA LMT GIS XOM O.PRF TWX OPRF CVS ABT NKE HON AAPL ABBV DIS ABT VTR HON SO GILD O MA TWC RB CMI TGT V AFL PEP JNJ CVX DG MSFT SBUX ABBV QCOM
The biggest news this week was Pfizer’s (PFE - Free Report) announcement of its plans to re-organize its business into three new segments, effective next year. J&J (JNJ - Free Report) was ordered by a St Louis jury to pay approximately $4.7 billion to nearly two dozen women in a lawsuit related to its talc-based products. Merck (MRK - Free Report) , AbbVie (ABBV - Free Report) and Bristol-Myers (BMY - Free Report) provided updates on their cancer drugs.
AZN AZN CTIC ABBV CTI PFE SAM ABBV
Johnson & Johnson (JNJ - Free Report) has one of the most diverse revenue streams in the industry within the pharmaceutical division, which accounts for almost half of its revenues. The company has several multi-million dollar drugs covering a broad range of areas such as neuroscience, cardiovascular and metabolism; immunology, oncology, pulmonary hypertension,, and infectious diseases/vaccines. However, like many of its peers, J&J is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
JNJ ABBV SAM ABBV HLUYY
Funny thing about your birthday falling on the 13th of the month is that it can create some very odd feelings of doom. Not great when you're looking to stay in the markets! With Advaxis (NASDAQ:ADXS) taking its dive into new lows, this writer's birthday feel all that much worth celebrating.
ADXS ABBV ABBV
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections.
SNWW AST ACHV URGN CDXC OVID AUPH SNWV DRNA AKCA TORC AUP AST.WS OSIR AGN MRK IONS NVS ABBV RMD BMY ABBV
43 of 101 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive 1-year returns and free cash-flow yields greater than their dividend yields as of 7/9/18.
DLR.PRH DLR.PRG HCN PM DLR.PRJ PFG DLR.PRI WELL.PRI O.PRF MET STX OPRF PRU VZA IP CUKPF CCL WELL ABBV VTR PRU F INPAP PFK O CCL HCN.PRJ CUK HCN.PRI SPG.PRJ PRH CVX VZ VTRB SPG ABBV DLR QCOM DLR.PRC DLR.PRF PJH IVZ
AbbVie (ABBV - Free Report) announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study – DBL3001 – evaluating it as first-line treatment for diffuse large B-cell lymphoma (“DLBCL”). The drug failed to improve event-free survival (“EFS”) compared to current standard of care.
BIIB JNJ ABBV ABBV
14h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
15h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET